Log In
BCIQ
Print this Print this
 

tigapotide (PCK3145)

  Manage Alerts
Collapse Summary General Information
Company Zein Biotec plc
DescriptionSynthetic peptide analog of prostate secretory protein (PSP94)
Molecular Target Laminin receptor
Mechanism of ActionMatrix metalloproteinase inhibitor (MMPI)
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat castration-resistant prostate cancer (CRPC); Treat metastatic prostate cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$15.0M

$0.2M

$14.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/27/2009

$15.0M

$0.2M

$14.8M

Get a free BioCentury trial today